% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Richlitzki:299589,
author = {C. Richlitzki and F. Manapov and A. Holzgreve and M. Rabe
and R. A. Werner and C. Belka$^*$ and M. Unterrainer and C.
Eze},
title = {{A}dvances of {PET}/{CT} in {T}arget {D}elineation of
{L}ung {C}ancer {B}efore {R}adiation {T}herapy.},
journal = {Seminars in nuclear medicine},
volume = {55},
number = {2},
issn = {0001-2998},
address = {New York, NY [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2025-00530},
pages = {190-201},
year = {2025},
note = {2025 Mar;55(2):190-201},
abstract = {In the clinical management of lung cancer, radiotherapy
remains a cornerstone of multimodal treatment strategies,
often used alongside surgery or in combination with systemic
therapies such as chemotherapy, tyrosine kinase inhibitors,
and immune checkpoint inhibitors. While conventional imaging
modalities like computed tomography (CT) and magnetic
resonance imaging (MRI) continue to play a central role in
staging, response assessment, and radiotherapy planning,
advanced imaging techniques, particularly [18F]FDG PET/CT,
are being increasingly integrated into routine clinical
practice. These advanced techniques address the limitations
of standard imaging by providing insight into molecular and
metabolic tumor characteristics, enabling precise tumor
visualization, accurate target volume delineation, and early
treatment response assessment. This review examines the role
of radiotherapy in the multidisciplinary management of lung
cancer, detailing current concepts of morphological and
functional imaging for staging and treatment planning. It
also highlights the growing importance of PET-based
radiotherapy planning, emphasizing its contributions to
target volume definition and predictive value for treatment
outcomes. Recent methodological advances, including the
integration of artificial intelligence (AI), radiomics,
technical innovations, and novel PET ligands, are discussed,
highlighting their potential to improve the precision,
efficacy, and personalization of lung cancer radiotherapy
planning.},
subtyp = {Review Article},
cin = {MU01},
ddc = {610},
cid = {I:(DE-He78)MU01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40064578},
doi = {10.1053/j.semnuclmed.2025.02.013},
url = {https://inrepo02.dkfz.de/record/299589},
}